FGFR2 and cholangiocarcinoma: Second, in addition to confirming previous reports that FGFR2 fusions and other rearrangements in cholangiocarcinoma are sensitive to FGFR inhibition10,12,30,31, this study showed in a dedicated cohort of FGFR-mutated tumors that specific FGFR2 SNVs, namely C382R and in-frame deletions, are associated with response to pemigatinib, suggesting that FGFR inhibitors may be effective in cholangiocarcinoma with FGFR2 alterations other than fusions and rearrangements.